Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives
Future Medicinal Chemistry · 18.04.2026 · 18 (8) · 993-1006
DOI: 10.1080/17568919.2026.2636498 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, online erschienen am 24.02.2026. Verfasst von Hamada S Abulkhair. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt. Hauptthemen laut MEDLINE: Pyridones, Antineoplastic Agents, Enhancer of Zeste Homolog 2 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt.
ORCID-Profile: Hamada S Abulkhair
Zitieren
APA
Abulkhair, H. S. (2026). Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives. Future Medicinal Chemistry, 18(8), 993-1006. https://doi.org/10.1080/17568919.2026.2636498
Vancouver
Abulkhair HS. Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives. Future Medicinal Chemistry. 2026;18(8):993-1006. doi:10.1080/17568919.2026.2636498
BibTeX
@article{Abulkhair2026,
author = {Abulkhair, Hamada S},
title = {Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives},
journal = {Future Medicinal Chemistry},
year = {2026},
volume = {18},
number = {8},
pages = {993--1006},
doi = {10.1080/17568919.2026.2636498}
}
EUVIMED